This is a working overview of Cardarine, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
=== R139w === One further single nucleotide polymorphism, found homozygous in 0% to 5% of different ethnic population, is leading to an amino acid exchange on position 139 from arginine to tryptophane. Furthermore, an alternative RNA splicing site is created leading to a loss of the quinone binding site. The variant protein of NQO1*3 has similar stability as its wild-type counterpart. The variation between the two is substrate specific and it has reduced activity for some substrates. It has been recently shown that the NQO1*3 polymorphism may also lead to reduced NQO1 protein expression.
=== Bill Adler === Bill Adler (Trevor White) is the global head of FICC (Fixed Income, Currencies and Commodities) at Pierpoint, and is based out of the New York headquarters. Adler is a ruthless pragmatist fiercely devoted to the firm; he is also a longtime friend of Eric, who initially hired him, but as his senior, he is shown to feel entitled to Eric's loyalty and support. Adler first appears in the series 1 finale to vet new grads on the RIF day. He makes Harper a deal to reinstate Eric after she got him fired for his verbal abuse in the workplace. In series 2, Eric visits Adler in New York following the loss of Felim Bichan as a client and confronts him over reduced compensation for his team and the rumored consolidation of the London and New York desks. Adler rebuffs Eric, citing his underperformance, and sidelines him in a non-trading role. DVD later goes to Adler to report client Nicole Craig's sexual assault of new hire Venetia Berens, but Adler tells him to bury the case. When Harper and Eric go to Adler proposing a leaner London office and threaten to publicize Pierpoint's culture of suppression, Adler accepts their terms, consolidating CPS and FX and allowing DVD to be dismissed. In series 3, Adler supports Eric’s promotion to partner but orders him to fire a trader to demonstrate authority, leading Eric to dismiss Kenny Kilbane. Adler intervenes directly on the trading floor during the Lumi IPO to reassure investors.
== Occurrence == Carotenoids are essential for animal health and functioning, but animals cannot produce them. Animals obtain carotenoids from their diet, with herbivores sourcing them from plants or algae, and carnivores, in turn, sourcing them from herbivores. Meso-zeaxanthin is not present in plants, except for marine species. Originally, it was suggested that meso-zeaxanthin present in humans and other vertebrates was non-dietary in origin, instead being biosynthesized in the macula (the central part of the retina) from retinal lutein (another xanthophyll carotenoid found in the human diet); this work has since been refuted. Consistent with work by Maoka et al. in 1986, Nolan et al. showed that meso-zeaxanthin is present in the skin of trout, sardine and salmon, and in the flesh of trout. In a subsequent publication, Nolan's group detected and quantified the three stereoisomers of zeaxanthin, including meso-zeaxanthin, in the flesh of two different trout species, which was the first report of concentrations of meso-zeaxanthin in habitually consumed food. Prior to this research, a publication from Khachick et al. (2002) reported that liver from Japanese quail (Coturnix japonica) and frog plasma contain meso-zeaxanthin. Meso-zeaxanthin may be generated from other carotenoids consumed by animals, as carotenoids can be interconverted for functional reasons. For example, it has been suggested that meso-zeaxanthin of trout integuments is derived from astaxanthin, and meso-zeaxanthin in primates is derived at least in part from lutein.
== Computational challenges == The sequencing technologies described here produce raw data that needs to be assembled into longer sequences such as complete genomes (sequence assembly). There are many computational challenges to achieve this, such as the evaluation of the raw sequence data which is done by programs and algorithms such as Phred and Phrap. Other challenges have to deal with repetitive sequences that often prevent complete genome assemblies because they occur in many places of the genome. As a consequence, many sequences may not be assigned to particular chromosomes. The production of raw sequence data is only the beginning of its detailed bioinformatical analysis. Yet new methods for sequencing and correcting sequencing errors were developed.
=== Nomenclature === In order to categorize a mutation as such, the "normal" sequence must be obtained from the DNA of a "normal" or "healthy" organism (as opposed to a "mutant" or "sick" one), it should be identified and reported; ideally, it should be made publicly available for a straightforward nucleotide-by-nucleotide comparison, and agreed upon by the scientific community or by a group of expert geneticists and biologists, who have the responsibility of establishing the standard or so-called "consensus" sequence. This step requires a tremendous scientific effort. Once the consensus sequence is known, the mutations in a genome can be pinpointed, described, and classified. The committee of the Human Genome Variation Society (HGVS) has developed the standard human sequence variant nomenclature, which should be used by researchers and DNA diagnostic centers to generate unambiguous mutation descriptions. In principle, this nomenclature can also be used to describe mutations in other organisms. The nomenclature specifies the type of mutation and base or amino acid changes.
Sources: en.wikipedia.org
=== Former programming === Formerly, Bryant Park hosted New York Fashion Week (NYFW) shows, which took over the park for two weeks in the winter and late summer each year. NYFW, which moved to Bryant Park in 1993, was forced to set fees for its shows after Manhattan Community Board 5 disapproved of a free fashion show on the grounds that three-fourths of profits would go to BPC and only one-fourth to NYC Parks. Dan Biederman of the BPC had called the profits from NYFW "a million dollars I would happily do without," and lamented the fact that NYFW took over the park at two high-traffic periods: late summer and late winter. NYFW moved from Bryant Park in 2010 after disagreements with the BPC.
== Q == Juda Hirsch Quastel FRS (1899–1987). British-Canadian biochemist at the Rothamsted Experimental Station and McGill University, known for research in neurochemistry, metabolism and cancer. Osbourne Quaye. Ghanaian biochemist
A material-dependent unit used in nuclear and particle physics and engineering to measure the thickness of shielding, for example around a nuclear reactor, particle accelerator, or radiation or particle detector. 1 mwe of a material is the thickness of that material that provides the equivalent shielding of one metre (≈39.4 in) of water. This unit is commonly used in underground science to express the extent to which the overburden (usually rock) shields an underground space or laboratory from cosmic rays. The actual thickness of overburden through which cosmic rays must traverse to reach the underground space varies as a function of direction due to the shape of the overburden, which may be a mountain, or a flat plain, or something more complex like a cliff side. To express the depth of an underground space in mwe (or kmwe for deep sites) as a single number, the convention is to use the depth beneath a flat overburden at sea level that gives the same overall cosmic ray muon flux in the underground location.
However, since each SNP requires a distinct probe, the TaqMan assay is limited by the how close the SNPs can be situated. The scale of the assay can be drastically increased by performing many simultaneous reactions in microtitre plates. Generally, TaqMan is limited to applications that involve interrogating a small number of SNPs since optimal probes and reaction conditions must be designed for each SNP.
=== Marijuana === Moore supported legislation introduced and passed during the 2022 legislative session that created a ballot referendum to legalize recreational marijuana in Maryland, and another bill that would regulate marijuana possession should the referendum pass in November. During his 2022 gubernatorial campaign, Moore talked about implementing a recreational cannabis industry with a focus on equity "so that communities that have experienced the greatest disparities benefit the most." Question 4 passed with 67.2 percent of voters approving the measure on November 8, 2022. In January 2023, Moore signed an executive order releasing $46.5 million to start developing the framework for a recreational marijuana industry in the state, with a majority of the released funds going toward grants for minority-owned firms. In May 2023, he signed a bill regulating the state's recreational marijuana industry. In October 2022, Moore praised President Joe Biden's pardon of thousands of people convicted of marijuana possession under federal law, and said that he would "fight to expunge the records of those arrested for marijuana possession [as governor]". In June 2024, Moore signed an executive order pardoning about 100,000 people with low-level cannabis-related convictions in Maryland. In June 2025, he pardoned an additional 6,900 individuals convicted of simple cannabis possession. In May 2023, Moore allowed a bill that prohibits police from stopping a vehicle solely based on if they smell marijuana to become law without his signature.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.